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Background: The median life expectancy of cystic ﬁbrosis (CF) patients has increased dramatically over the last few years and we now observe a
subset of patients with a body mass index (BMI) exceeding 25 kg/m2. The aim of this study was to characterize these individuals and to identify
factors associated with higher BMI.
Methods: This is a cross sectional study including 187 adult CF subjects. Percent predicted forced expiratory volume in 1 s (%FEV1), blood lipid
proﬁles as well as fasting glucose and insulin levels were evaluated. Subjects also had an oral glucose tolerance test (OGTT) and the area under the
curve (AUC) for glucose and insulin was calculated. CF subjects were then stratiﬁed according to the following BMI categories: underweight:
BMI≤18.5 kg/m2; normal weight: 18.5 kg/m2bBMIb25 kg/m2; and overweight or obese: BMI≥25 kg/m2.
Results: Overweight subjects were older and less likely to have enzyme supplementation compared to the other two groups. Furthermore, this
group exhibits higher levels of fasting insulin, total and LDL-cholesterol as well as insulin AUC. Further analyses demonstrated that BMI corre-
lated with %FEV1, fasting insulin, insulin AUC, total cholesterol, LDL-cholesterol and the ratio of HDL-cholesterol to total cholesterol and that
%FEV1, insulin AUC and LDL-cholesterol were independent associated with BMI.
Discussion: Overweight CF subjects have higher fasting insulin and insulin AUC as well as total and LDL-cholesterol. Furthermore, we also dem-
onstrated that LDL-cholesterol, insulin AUC are independently associated with BMI in a population of adult CF subjects.
© 2012 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: LDL-cholesterol; Insulin; Body mass index; Cystic ﬁbrosis; Lung function1. Introduction
Cystic fibrosis (CF) is the most common lethal autosomal dis-
ease affecting Caucasian individuals with an incidence of 1 per
3608 in live births in Canada in 2000 [1]. Pulmonary disease is⁎ Corresponding author at: Institut de recherches cliniques de Montréal, 110
avenue des Pins Ouest, Montréal, QC, Canada H2W 1R7. Tel.: +1 514 987
5666; fax: +1 514 987 5670.
E-mail address: remi.rabasa-lhoret@ircm.qc.ca (R. Rabasa-Lhoret).
1569-1993/$ -see front matter © 2012 Published by Elsevier B.V. on behalf of Eur
doi:10.1016/j.jcf.2012.03.006the primary clinical manifestation and the major cause of death in
CF patients. In addition, approximately 90% of CF patients have
exocrine pancreatic insufficiency, leading to malabsorption, mal-
nutrition, poor weight gain and low body mass index (BMI) [2]
Numerous studies have shown the strong positive relationship be-
tween BMI and lung function [3,4]. Furthermore, BMI is an impor-
tant predictor of survival in CF patients [5,6]. Thus, factors
associated with higher BMI are of critical importance for CF out-
comes. With the advancement of clinical care and nutritional mon-
itoring, most CF patients now reach their target weight and theopean Cystic Fibrosis Society.
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40 years old in Canada [7]. Furthermore, we now observe the
emergence of a subset of CF patients who are considered over-
weight or obese (BMI≥25 kg/m2). However, whether these indi-
viduals have a better or worse clinical and metabolic profile
compared to normal weight CF individuals is unknown at present.
The aim of this study was to characterize overweight CF subjects
and to identify factors associated with higher BMI.
2. Subjects and methods
2.1. Subjects
Baseline data of the first 187 subjects included in the Mon-
treal Cystic Fibrosis Cohort (MCFC) were used for the analysis.
The MCFC was established in 2004 as part of an ongoing sys-
tematic screening program to detect CF related diabetes
(CFRD) using the oral glucose tolerance test (OGTT) [8]. The
main objective of this prospective observational cohort is to
study mechanisms associated with glucose intolerance as well
as the association of pre-diabetic states with CF outcomes.
The protocol was approved by the Research Ethics Committee
of the Centre hospitalier de l'Université de Montréal and all
participants gave informed written consent before participation.
CF subjects included in the analysis were over 18 years of
age and with no previously diagnosed diabetes. Exclusion cri-
teria were exacerbation in the previous month defined by
changes in sputum production (volume, color, consistency),
new or increased hemoptysis, cough, increased dyspnea, fa-
tigue or lethargy, fever, anorexia, sinus pain, a 10% decrease
in pulmonary function determined by forced expiratory volume
in 1 s (FEV1) from previous values (recorded every 3 months),
intravenous antibiotic treatment, the use of medications or con-
ditions that interfere with glucose metabolism, steroids (oral or
intravenous), growth hormone, megace, transplantation or
pregnancy. Exacerbation was identified on the same day by a
trained CF pneumologist blinded to the metabolic parameters.
2.2. CF status and anthropometric data
Pulmonary function (FEV1 (L/sec) and predicted%FEV1) was
measured by spirometry on the day of the OGTT (Medgraphic
1870, St-Paul, MN, USA). Pancreatic insufficiency was defined
by current enzyme supplementation. CF genotypes were
extracted from the medical files. Numerous studies have shown
a strong correlation between genotype and exocrine pancreatic
function. They also showed that the milder mutation has a domi-
nant phenotypic effect [9,10]. Thus, patients abhorring severe
mutation on both alleles were classified as “severe”while patients
having as least one allele associated with a milder phenotype
were classified as “moderate to mild” (http://www.genet.
sickkids.on.ca and [9–12]). Patients abhorring unknown muta-
tions were excluded from the statistical analysis.
Body weight was measured using an electronic scale (Tanita
Corporation Arlington heights, IL, USA) and standing height
by a wall stadiometer. BMI was calculated using weight in kilo-
grams divided by height in meters (kg/m2).2.3. Oral glucose tolerance test (OGTT)
All subjects underwent a 2-h OGTT. After an overnight fast,
they ingested, in less than 5 min, a glucose solution: 1.75 g/kg
of body weight to a maximum of 75 g according to the Canadian
Diabetes Association guidelines [13]. Plasma glucose and insulin
concentrations were measured at 0, 30, 60, 90 and 120 min. Plas-
ma glucose was determined immediately in duplicate by the glu-
cose oxidase method (Beckman Coulter, Fullerton, CA, USA).
Insulin levels were determined in duplicate using human insulin
Radio Immuno Assay (Linco Research Inc. St-Charles, MO,
USA).
2.4. Biochemical dosages
Total cholesterol, triglycerides and HDL-cholesterol were
measured by enzymatic reaction (ADVIA1650, Bayer Health
Care Diagnostics). Total cholesterol, HDL-cholesterol and tri-
glycerides were used in the Friedewald formula to calculate
LDL-cholesterol concentration [14].
2.5. Statistical analysis
Data are presented as mean±standard deviation (SD). Glu-
cose and insulin AUC were calculated using Graphpad Prism
4.0 for Windows. Subjects were stratified by BMI as previously
described [15,16]: underweight: BMI ≤18.5 kg/m2; normal
weight: 18.5 kg/m2bBMIb25 kg/m2; and overweight or obese:
BMI≥25 kg/m2.
Group differences were determined by analyses of variance
(ANOVA) or CHI square as appropriate. Associations were deter-
mined using Pearson correlation (n=127 subjects). We then used
hierarchical linear regression to examine the contribution of these
variables to BMI. The following variables were associated with
BMI and were thus included in the first model: age, genotype, en-
zyme supplementation and sex. We then assessed additional
models for the independent contribution of variables that were sig-
nificantly associated with BMI. The statistical analysis was per-
formed with SPSS for Windows (Version 16.0 SPSS, Chicago,
IL). Significance was accepted at pb0.05.
3. Results
As shown in Tables 1 and 3, the 187 subjects displayed impor-
tant variation in lung function, BMI and metabolic profile. As
shown in Table 2, analysis of BMI distribution showed that
75% of our cohort had normal BMI while 13% were under-
weight, 11% were overweight and one subject was obese
(BMI=30.6). We did all analysis with or without the obese sub-
ject and observed similar results. We did not find any significant
difference among BMI categories for sex. On the other hand, we
observed significant differences among the groups for enzyme
supplementation (p=0.01) and genotype (p=0.048). As reported
previously [17,18], we found a strong association between geno-
type and enzyme supplementation (p=0.001). Thus, more than
90% of underweight subjects had severe mutation on both alleles
as well as enzyme supplementation. In contrast, the prevalence of
Table 1
Clinical characteristics of cystic fibrosis subjects (n=187).
Characteristics Mean±SD Range
Age (years) 26.3±7.6 18–49
%FEV1 70±21 19–119
Sex (% women) 48.1
Genotype
Severe (%) 71.7
Mild to moderate (%) 14.4
Unclassified (%) 13.9
Pancreatic enzyme supplementation (n=184) 83
Body mass index (kg/m2) 21.5±3.0 13.1–30.6
FEV1: Forced Expiratory Volume in 1 s.
Table 3
Metabolic characteristics of cystic fibrosis subjects by categories of BMI.
Characteristics BMI (kg/m2) Range
≤18.5 Between 18.5
and 25
≥25
n=25 n=141 n=21
Fasting glucose
(mmol/l)
5.7±1.1 5.4±0.8 5.4±0.4 3.8–9.3
Glucose 120 min
(mmol/l)
9.1±4.9 7.9±3.1 7.8±2.6 2.3–18.8
Glucose AUC 528±261 466±231 411±189 89–1199
Fasting insulin
(pmol/l)
8.9±2.5 9.7±4.0 11.9±3.3 a 2.00–27.6
Insulin AUC 2827 ±1393 3467±2114 4837±2192 a,b 335–11,906
Triglycerides
(mmol/l)
1.01±0.08 1.05±0.04 1.26±0.14 0.35–3.24
Cholesterol
(mmol/l)
3.1±0.8 3.5±1.0 4.2±0.8 a,b 1.7–7.1
HDL-C
(mmol/l)
1.2±0.4 1.2±0.3 1.2±0.2 0.59–2.28
LDL-C
(mmol/l)
1.4±0.6 1.9±0.8 a 2.4±0.8 a,b 0.63–4.87
TC/HDL-C 2.63±0.58 3.02±0.71 3.61±0.73 a,b 1.6–5.6
a pb0.05 significantly different compared to subjects with BMI≤18.5.
b pb0.05 significantly different compared to subjects with BMI between 18.5
and 25.
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group was 54% and 62%, respectively. Furthermore, overweight
subjects were significantly older than either underweight or nor-
mal weight individuals while underweight subjects had worse
lung function compared to the two other groups (Table 2).
As shown in Table 3, overweight subjects exhibited higher
fasting insulin levels, insulin AUC, fasting cholesterol levels
as well as a ratio of cholesterol/HDL-cholesterol compared to
the other two groups. Furthermore, we observed a significant
progressive increase in the level of LDL-cholesterol with in-
creasing BMI categories. It should be noted, however, that the
cholesterol values remain in the normal range for all groups
[19].
We next examined the association between BMI and various
metabolic parameters using Pearson correlations. BMI correlat-
ed positively with age (r=0.33; pb0.01), %FEV1 (r=0.32;
pb0.01), fasting insulin (r=0.20; pb0.01); insulin AUC
(r=0.20; pb0.01), triglycerides (r=0.17; pb0.05), total choles-
terol (r=0.37; pb0.01) and LDL-cholesterol (r=0.42; pb0.01)
and the ratio of total cholesterol/HDL-cholesterol (r=0.41;
pb0.01). Except for triglycerides, these correlations remained
statistically significant after correcting for age, genotype, sex,
and enzyme supplementation. We next determined which of
these variables were independently associated with BMI in
our cohort. As shown in Table 4, LDL-cholesterol, %FEV1,
and insulin AUC remained independently associated with BMITable 2
Clinical characteristics of cystic fibrosis subjects by BMI category.
Characteristics BMI (kg/m2)
≤18.5 Between 18.5 and 25 ≥25
n=25 n=141 n=21
Age (years) 23.8±5.2 25.8±7.6 32.5±7.8 a,b
%FEV1 56±19 71±21
a 79±21 a
Sex (men/women) 11/14 72/69 14/7
Genotype (%)
Severe (%) 92 70.9 54.2
Mild to moderate (%) 4 14.2 28.6
Unclassified (%) 4 14.9 19
Enzyme supplementation (%) 95.8 83.5 61.9
Genotype p=0.048.
Pancreatic supplementation p=0.01.
a pb0.05 signiﬁcantly different compared to subjects with BMI≤18.5.
b pb0.05 signiﬁcantly different compared to subjects with BMI between 18.5
and 25.after correcting for sex, age, genotype, and enzyme supplementa-
tion in CF subjects. Together, these variables explained 35% of
the variance of BMI.
4. Discussion
Current CF Foundation guidelines recommend that BMI be
maintained at≥22 kg/m2 for women and≥23 kg/m2 for men
[20]. This is slightly higher than the average BMI observed in
our cohort which is 21±2.9 and 22±3.0 kg/m2 for men and
women, respectively. Based on these recommendations, only
33% of our subjects are above the recommended BMI, which
highlights the importance of identifying factors positively asso-
ciated with BMI.
In our study, 13% of CF subjects were classified as over-
weight. This is similar to Kastner-Cole et al. who reported a
prevalence of 10% for overweight and obese in CF patients ho-
mozygous for delta508 mutation [21]. Approximately 17% of
the cohort did not have pancreatic enzyme supplementation,
which is in a similar range than the 14% reported by the Cana-
dian Cystic Fibrosis Patient Data Registry Report [7].Table 4
Stepwise regression analysis of independent predictors of BMI (n=130).
Dependent
variable
Step Predictor R R2 R
change
P
value
BMI 1 Enzyme, sex, age
genotype
0.416 0.173 0.173 0.001
BMI 2 %FEV1 0.516 0.266 0.093 0.001
BMI 3 LDL-cholesterol 0.572 0.327 0.060 0.004
BMI 4 Insulin AUC 0.599 0.359 0.033 0.007
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higher proportion of overweight individuals abhorred CFTR
mutations associated with milder phenotypes and did not have
enzyme supplementation. Overweight patients were also char-
acterized by higher levels of fasting insulin, total cholesterol,
LDL-cholesterol as well as increased insulin AUC. To our
knowledge, this is the first characterization of overweight
CF individuals with respect to metabolic parameters and the
first demonstration of an independent association between
LDL-cholesterol and BMI in CF subjects.
Analysis of the complete study sample showed a strong posi-
tive association between %FEV1 and BMI and showed that BMI
is independently associated with %FEV1. Other studies have
demonstrated a similar association in CF individuals [3,4,20]
and it has been suggested that lung disease contributes to altered
body composition [22,23]. One possible mechanism to this rela-
tionship is the increase in resting metabolic rate observed with
the progression of lung disease which, when combined with mal-
absorption and negative caloric balance during periods of infec-
tion, may lead to lower BMI [24]. Importantly for CF patients,
those who are overweight exhibit reduced probability of death
at 5 years compared to those with normal weight [24]. While un-
derweight patients showed lower %FEV1 compared to the other
two groups, we did not observed any significant difference be-
tween overweight and normal weight individuals for this param-
eter. In contrast to children, there seem to be a clinical threshold
in CF adults beyond which higher BMI does not translate into
higher %FEV1 [21]. Together, these results highlight the impor-
tance of BMI in CF outcome.
Our data highlighted important differences among BMI
groups for genotype. Thus, 92% of underweight subjects exhibit
mutations associated with severe phenotype while its prevalence
was only 54.2% in overweight group. As previously shown
[9,11], we observed a strong correlation between CFTR genotype
and phenotype of the exocrine pancreas. Thus, the overweight
group has a lower proportion of individuals with severe mutation
as well as enzyme supplementation compared to the other groups.
It should be noted, however, that more than 54.2% of overweight
individuals have severe CFTR mutations and of those, 33% are
homozygous for the delta508 mutation. This wide variation of
BMI between patients bearing identical CFTR mutations sug-
gests that additional factors either genetic or environmental may
contribute to the phenotype. Importantly, we observed that sub-
jects with milder phenotypic CFTR mutations also had higher in-
sulin AUC. Whether this difference in insulin AUC are due only
to disruption of islet architecture due to fibrosis and fatty infiltra-
tion of the pancreas or whether other mechanism such as amyloid
deposit or diabetes specific mutations contribute to these differ-
ence remains to be investigated. Interestingly, there was no asso-
ciation between fasting insulin and either genotype or enzyme
supplementation.
Our results also demonstrated that insulin AUC was inde-
pendently associated with BMI in CF subjects. Insulin is an im-
portant anabolic hormone and recent studies have demonstrated
that insulin therapy may prevent BMI loss in patients with
CFRD [25]. Similarly, Mohan et al. [26] have reported that in-
sulin administration for 3 years to CFRD subjects lead toimproved BMI. Furthermore, there is a significant relationship
between insulin AUC and linear growth velocity in CF children
[27]. Further studies should further investigate the relationship
between insulin and BMI in CF patients.
We observed lower LDL-cholesterol values and reduced
%FEV1 in underweight CF patients. In the complete study sam-
ple, we observed a strong positive association between BMI
and LDL-cholesterol levels in CF individuals. Furthermore, our
analysis revealed that LDL-cholesterol is independently associat-
ed with BMI in this population. Low LDL-cholesterol has been
observed in critically ill patients [28,29] as well as in individuals
with chronic infections and sepsis [30,31]. Furthermore, low cho-
lesterol level is a predictor of mortality in acute kidney injury and
in critically ill surgical patients [30,32–34] and it had been sug-
gested that hypocholesterolemia may be used as a marker of dis-
ease severity [29,35]. Whether this also apply to CF subjects
remains to be demonstrated.
The present study included only CF subjects with de novo
diabetes to avoid confounding factors such as insulin treatment.
Furthermore, our study included mostly CF subjects with mild
to moderate lung disease. Therefore, whether our results extend
to more severely affected CF patients remain to be investigated.
In conclusion, the present results provide new evidence of
the association of BMI with LDL-cholesterol and insulin
AUC in a population of adult CF subjects with mild to moder-
ate lung disease. Further studies should examine the association
between LDL-cholesterol and insulin levels and BMI in CF in
non-diabetic subjects.
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